Revenue

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Stunning new US/EU data for BTK inhibitor orelabrutinib signals a major push into Western markets, challenging established blood cancer therapies.

Amidst market headwinds and rising costs, a new global imperative for energy security is reshaping offshore wind from a climate goal to a strategic necessity.

Shifters' new AI-native ecosystem moves beyond remote control, enabling supervised robotic teams to enter dangerous zones first. What does this mean for safety?

A single bottle of Yamazaki 50-Year-Old just sold for HK$8.25M, shattering records. We deconstruct why this isn't just about whisky, but a seismic shift in luxury investing.

SWI Group's bold acquisition converts crypto infrastructure for AI's voracious appetite, proving that the next digital revolution will be won with raw power.

Questerre's HCCO® test in Brazil could unlock vast oil shale resources. But ESG questions and market risks loom large for the company's ambitious bet.

Defiance's new 2X SpaceX ETF arrives just after a record IPO, offering amplified returns. But are these complex products a new tool or a new trap?

A 76-year-old demolition firm's local award reveals a tectonic shift: in the modern economy, even heavy industry is built on a foundation of online reviews.

A new BCG report reveals a dangerous gap: 96% of CMOs see AI as transformative, but only 8% use it autonomously. The race is on to close this divide.

With demand for AI compute outpacing supply, a new partnership aims to deliver purpose-built infrastructure across South Korea on an accelerated timeline.

AV's new backpack UGV packs advanced mapping and comms relay tech. Is it enough to outmaneuver rivals and redefine reconnaissance for the modern soldier?

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

Beyond one-size-fits-all, GCL SI unveils specialized solar panels for deserts and oceans, backed by a blockchain-verified green supply chain. A new era begins.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

A small eco-resort just topped Tripadvisor's global charts. We dissect how Hamanasi’s regenerative model is not just good for the planet, but a masterclass in market dominance.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

A landmark 5GWh battery deal between Fox ESS and Solar Juice signals a major acceleration in Australia's energy transition. Here's how the partnership works.

A landmark 5GWh agreement between Fox ESS and OSW isn't just about storage; it’s a blueprint for a decentralized, resilient, and renewable-powered grid.

While Nevada's cannabis market contracts, C21 Investments posts record customer growth and an 8% revenue jump, fueled by a high-stakes tax challenge.